How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,257 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

/treatment Experimental: Normal, asymptomatic non-lens wearers Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed. Drug: Lifitegrast Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed. Other Name: Xiidra Experimental: Dry eye subjects, non-lens wearers Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed. Drug (...) : Lifitegrast Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed. Other Name: Xiidra Experimental: Contact lens wearers with discomfort Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed. Drug: Lifitegrast Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed. Other Name: Xiidra Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

82. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. (PubMed)

Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. We have developed nanoparticle γ-cyclodextrin dexamethasone (DexNP) and dorzolamide (DorzNP) eye drops that provide sustained high drug concentrations on the eye surface. To test these characteristics, we measured dexamethasone and dorzolamide levels in tear fluid in humans following eye drop administration.Concentration of dexamethasone was measured by mass spectrometry. One drop of DexNP was instilled into one eye (...) . Tear fluid was sampled with microcapillary pipettes at seven time-points after drop instillation. Control eyes received Maxidex(®) (dexamethasone). The same procedure was performed for dorzolamide with DorzNP and Trusopt(®) .Six subjects were included in each group. The peak concentration (μg/ml ± standard deviation) of dexamethasone for DexNP eye drops (636.6 ± 399.1) was up to 19-fold higher than with Maxidex(®) (39.3 ± 18.9) (p < 0.001). At 4 hr, DexNP was still 10 times higher than Maxidex(®

Full Text available with Trip Pro

2014 Acta ophthalmologica

83. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. (PubMed)

Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. To compare preservative-free ketotifen 0.025% ophthalmic solution to olopatadine 0.1% ophthalmic solution in with the treatment of seasonal allergic conjunctivitis (SAC) in clinical practice.This was a comparative, randomised, investigator-masked, pilot clinical study in adult patients with documented history of SAC (...) and presenting with moderate to severe itching and conjunctival hyperemia. Eligible patients initiated either ketotifen or olopatadine treatment at a dose of one drop twice daily for 28days. The resolution of ocular signs and symptoms was assessed on day 7 and day 28. Itching was also assessed within 15minutes following the first instillation (day 0). Conjunctival impression cytology was performed at each visit to assess the evolution of ICAM-1 expression (day 0, 7 and 28).Seventy-five patients were

2014 Journal français d'ophtalmologie

84. CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. (PubMed)

CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. To evaluate pazopanib 10 mg/mL eye drops (pazopanib) in healthy subjects and in subjects with previously untreated subfoveal choroidal neovascularization secondary to age-related macular degeneration.Study 1 (single center, randomized, placebo-controlled, double-masked) included 3 cohorts of 12 to 13 healthy subjects each who instilled pazopanib or placebo 4 times (...) ) (primary endpoint), retinal morphology, choroidal neovascularization size, or total lesion size. Complement Factor H genotype had no effect on changes from baseline in the best-corrected visual acuity or central retinal thickness. The most common pazopanib-related ocular adverse events included eye irritation (Study 1, n = 7) and instillation site pain (Study 2, n = 3). No serious adverse events were reported.Pazopanib was well tolerated. In subjects with previously untreated neovascular age-related

2014 Retina (Philadelphia, Pa.)

85. Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. (PubMed)

AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg/ml instilled 3 (n=72) or 4 times daily (n=74); pazopanib 10 mg/ml instilled 2 (n=73), 3 (n=73), or 4 times daily (n=72); or ranibizumab injection administered once every 4 weeks (n=73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.The main (...) Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops.A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose

2014 Ophthalmology

86. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. (PubMed)

Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. We have developed nanoparticle γ-cyclodextrin dexamethasone (DexNP) and dorzolamide (DorzNP) eye drops that provide sustained high drug concentrations on the eye surface. To test these characteristics, we measured dexamethasone and dorzolamide levels in tear fluid in humans following eye drop administration.Concentration of dexamethasone was measured by mass spectrometry. One drop of DexNP was instilled into one eye (...) . Tear fluid was sampled with microcapillary pipettes at seven time-points after drop instillation. Control eyes received Maxidex(®) (dexamethasone). The same procedure was performed for dorzolamide with DorzNP and Trusopt(®) .Six subjects were included in each group. The peak concentration (μg/ml ± standard deviation) of dexamethasone for DexNP eye drops (636.6 ± 399.1) was up to 19-fold higher than with Maxidex(®) (39.3 ± 18.9) (p < 0.001). At 4 hr, DexNP was still 10 times higher than Maxidex(®

Full Text available with Trip Pro

2014 Acta ophthalmologica

87. Prophylactic Treatment: Lessdropsâ„¢ vs Standard Drops Regimen

: No Criteria Inclusion Criteria: Subject is undergoing bilateral cataract extraction or refractive lens exchange with intraocular lens implantation. Willing and able to provide written informed consent for participation in the study. Willing and able to comply with scheduled visits and other study procedures. Willing and able to administer eye drops and record the times the drops were instilled. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6-15 days between (...) , LLC Collaborators: Science in Vision Imprimis Pharmaceuticals, Inc. Information provided by (Responsible Party): Carolina Eyecare Physicians, LLC Study Details Study Description Go to Brief Summary: To compare the use of a compounded eye drop containing an antibiotic, a non-steroidal and steroidal anti-inflammatory to standard of care that is the use of 3 different topical medications to prevent inflammation and infection after routine cataract surgery. Condition or disease Intervention/treatment

2018 Clinical Trials

88. Efficacy of Mydriatic Drops in Premature Infants

: Drug used in the examination of premature infants. to investigate side effects of eye drops used Other Name: Tropicamide and mydfline used Outcome Measures Go to Primary Outcome Measures : The mean pupillary diameter [ Time Frame: an average of 1 year ] will be measured with a ruler after 60 minutes instillation of mydriatic Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) Summary: Because of the neonatologists reported that some infants had suffered from vomiting, bradycardia, hypotonia, and aspiration risk about 30-60 minutes after the fundus examination in the intensive care unit. The investigators observed the pupil dilation effects and side effects of tipple instillation of phenylephrine 2.5% plus tropicamide 0.5% ophthalmic drop combination which the investigators routinely used in ROP examination. Condition or disease Intervention/treatment Retinopathy

2018 Clinical Trials

89. Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction (PubMed)

, subjects underwent slit-lamp examination and completed MGD symptoms and dry eye-related quality of life score (DEQS) questionnaires. Meibum quality (meibum score) and meibomian gland loss (meiboscore) were evaluated. Tear lipid layer thickness was measured in both eyes with an ocular surface interferometer immediately after clinic arrival and 20 minutes after instillation of one drop of topical diquafosol.Thirteen patients (3 men, 10 women) with a mean age of 69.5±8.3 years completed the 3-month study (...) Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction To prospectively evaluate the effect of topical diquafosol sodium on eyes with dry eye disease (DED) and meibomian gland dysfunction (MGD).The subjects were consecutive patients diagnosed with both DED and MGD at Inouye Eye Hospital between March and September of 2016. The subjects were administered topical 3% diquafosol sodium ophthalmic solution six times a day for 3 months. At each study visit

Full Text available with Trip Pro

2017 Clinical ophthalmology (Auckland, N.Z.)

90. Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops

Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Dry Eye Using 0.03% Tacrolimus Eye (...) because the topical corticotherapy leads to ocular complications. The most used immunosuppressant is cyclosporine. Tacrolimus , another immunosuppressant, has been used in treatment of immune and inflammatory ocular diseases.This study describes a prospective controlled double-blinded randomized study of the clinical outcome of SS dry eyes patients treated with 0.03% tacrolimus eye drops. As secondary purposes, outcome of dry eye symptoms and any ocular symptoms of the eye drops were also questioned

2013 Clinical Trials

91. Interstitial cystitis: dimethyl sulfoxide bladder instillation

Interstitial cystitis: dimethyl sulfoxide bladder instillation Interstitial cystitis: dimeth Interstitial cystitis: dimethyl sulfo yl sulfoxide bladder xide bladder instillation instillation Evidence summary Published: 20 February 2014 nice.org.uk/guidance/esuom26 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in February 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA (...) : dimethyl sulfoxide bladder instillation (ESUOM26) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 6 of 28was found to be pregnant shortly after the first saline instillation and was removed from the study. Two patients in the placebo-first group dropped out before phase II of the trial. Assessment followed the completion of each treatment phase and comprised a subjective assessment by participants (participants were

2014 National Institute for Health and Clinical Excellence - Advice

92. The Impact of Hypo-osmolar Drops on Contact Lens Comfort

): Centre for Contact Lens Research, University of Waterloo Study Details Study Description Go to Brief Summary: This pilot study will investigate the impact of sterile saline drops that are formulated at hypo-osmolar levels on CL comfort in comparison to an iso-osmolar drop, in a group of symptomatic CL wearers. Condition or disease Intervention/treatment Phase Contact Lens Related Dry Eye Device: Hypo-osmolar drop 1 Device: Hypo-osmolar drop 2 Device: Iso-osmolar drop Not Applicable Study Design Go (...) Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Hypo-osmolar drop 1 Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops. Device: Hypo-osmolar drop 1 180 mOsmol sterile saline drops used as a contact lens rewetting drop. Experimental: Hypo-osmolar drop 2 Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity

2017 Clinical Trials

93. Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes. (PubMed)

Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes. The aim of this study was to evaluate by serial measurements, pupil mydriasis produced by topical application of tropicamide 1% using a spray in a closed eye or instillation in an open eye in adult and elderly populations.The research was done from February to April of 2011 in the Policlinica Ronaldo Gazolla, located in the Arcos da Lapa Campus of Estacio de Sá University, RJ- Brazil (...) . It was a clinical trial, controlled and randomized, made in a series of 50 patients that were being prepared for ophthalmoscopy examination. They were submitted to eye drop administration of 1% tropicamide in an open eye and to eyelid margin vaporization in a closed eye. The eyes were chosen for the administration of drops or spray according to a pseudo-random numbers table from Excel (2007) before application. The pupil diameter was measured before instillation and after 10, 20, and 30 min in both eyes

2012 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

94. An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

: November 1, 2012 Last Update Posted : April 12, 2017 Sponsor: Robin, Alan L., M.D. Information provided by (Responsible Party): Adam C. LePosa, Robin, Alan L., M.D. Study Details Study Description Go to Brief Summary: This is a prospective, observational, single-center study. Patients with at least 3 months of experience using topical medications for glaucoma and who state that they administer their own eye drops will be recruited. Subjects will be videotaped instilling a sterile artificial eye drop (...) , will be identified at the time of a regularly scheduled exam. If the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. All other patients who agree to participate will be enrolled. Upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation

2012 Clinical Trials

95. Tear lipid supplement prophylaxis against dry eye in adverse environments. (PubMed)

containing drop (Systane® Ultra) applied simultaneously to the contralateral eye. Subjects were subsequently exposed to a validated simulated adverse environment model created by a standing fan directed towards the eye, at a distance of 1m, for 2.5min. Low contrast glare acuity, lipid layer grade (LLG), non-invasive tear break-up time (NIBUT), temperature variation factor (TVF), and tear meniscus height (TMH) were evaluated at baseline, following eye drop instillation and following simulated adverse (...) Tear lipid supplement prophylaxis against dry eye in adverse environments. To compare the prophylactic efficacy of single application of lipid and non-lipid containing tear supplements, prior to exposure of symptomatic dry eye subjects to a simulated adverse environment.Thirty subjects with mild-to-moderate dry eye symptoms participated in the prospective, randomised, double-masked, paired-eye trial. A lipomimetic drop (Systane® Balance) was applied to one eye (randomised), and a non-lipid

2019 Contact lens & anterior eye : the journal of the British Contact Lens Association

96. Changes in pupil size and intraocular pressure after topical application of 0.5% tropicamide to the eyes of dogs sedated with butorphanol. (PubMed)

) or an equal volume of sterile saline (0.9% NaCl) solution. For each dog, 1 drop of 0.5% tropicamide ophthalmic solution was topically instilled in one eye and 1 drop of artificial tear solution was topically instilled in the other eye 10 minutes after the IM injection and again 5 minutes later. Extent of sedation, pupil size, and IOP were evaluated from 20 minutes before to 80 minutes after the IM injection and compared among treatment combinations.Butorphanol induced mild (n = 9) or moderate (3) sedation (...) Changes in pupil size and intraocular pressure after topical application of 0.5% tropicamide to the eyes of dogs sedated with butorphanol. To assess changes in pupil size and intraocular pressure (IOP) following topical application of a 0.5% tropicamide solution in the eyes of healthy butorphanol-sedated dogs.12 healthy adult Beagles.In a randomized crossover study consisting of 2 treatment periods with a 1-week washout between periods, dogs received an IM injection of butorphanol (0.2 mg/kg

2019 American journal of veterinary research

97. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial. (PubMed)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial. This study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% diquafosol (DQ).This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocated to use CN twice per day or DQ six times daily. Cornea (...)  = 0.0418, P = 0.0031 for Schirmer test). However, for DQ, TBUT showed significant improvement at 12 weeks only (P = 0.0281). Mean OSDI score differences from the baseline to 12 weeks were improved by - 13.03 ± 19.63 for CN and - 16.11 ± 20.87 for DQ, respectively (all P < 0.0001, P = 0.854 between groups). Regarding drug compliance, the mean instillation frequency of CN was less than that of DQ (P < 0.001). There were no statistically significant intergroup differences in safety evaluation.The level

2019 BMC Ophthalmology

98. Effect of Eye Masks on Neonatal Stress Following Dilated Retinal Examination: The MASK-ROP Randomized Clinical Trial. (PubMed)

in July 2017. Analysis was intention to treat.Patients were randomized to wear a phototherapy mask for a minimum of 4 hours after dilating drop instillation in addition to standard comfort measures.Number of desaturation, bradycardic, or apneic events during the 12-hour postexamination period.Of 51 infants who were examined, 28 (54.9%) were randomized to the treatment group (ie, used a mask) and 23 (45.1%) to the control group. Overall, 10 (35.7%) and 13 infants (56.5%) received ventilator support (...) Effect of Eye Masks on Neonatal Stress Following Dilated Retinal Examination: The MASK-ROP Randomized Clinical Trial. Although screening examinations for retinopathy of prematurity (ROP) prevent blindness, they are physiologically stressful for infants. Photosensitivity during mydriasis may contribute to postexamination stress, and reducing light stimulation may make infants more comfortable.To determine the effect of a phototherapy mask worn during mydriasis on infant stress in the 12-hour

2019 JAMA ophthalmology

99. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. (PubMed)

in China. Our study aims to compare the efficacy and safety profile of 0.05% CsA OE versus vehicle in Chinese patients with moderate to severe DED.This was a multicenter, randomized, double-masked, 2-parallel-arm, 3-month phase III study. Patients with moderate to severe DED were randomized to receive twice-daily 0.05% CsA OE or its vehicle, along with unpreserved hypromellose eye drops 3 times per day. Patients were followed up at day 7, 28, 56, and 84, as well as 2 weeks after the medications were (...) Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. Dry eye disease (DED) is a chronic ocular surface disease that affects hundreds of millions of people worldwide. Although 0.05% cyclosporine ophthalmic emulsion (CsA OE) has long been prescribed in the U.S. for the treatment of DED, it is not commercially available

2019 Medicine

100. [A new beta-blocking agent in the treatment of chronic open-angle glaucoma: timolol maleate. Effect of instillation of 1 drop on the intraocular pressure]. (PubMed)

[A new beta-blocking agent in the treatment of chronic open-angle glaucoma: timolol maleate. Effect of instillation of 1 drop on the intraocular pressure]. A total of 45 patients with chronic open-angle glaucoma were divided randomly into three groups of fifteen. Each patient in each group was given one drop into one eye (the other eye serving as a control), of either placebo, timolol 0,5%, or timolol 1,5%. The patients were observed for a period of seven hours, and results showed that timolol (...) was effective in reducing ocular tension when compared to placebo. It was also rapid in action (one to two hours after instillation), and no side-effects were noted. Timolol 0,5% appears to be as equally effective as the 1,5% strength.

1978 Journal français d'ophtalmologie

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>